Cargando…
Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study
AIMS: To analyze the potential role of synovial fluid peptidase activity as a measure of disease burden and predictive biomarker of progression in knee osteoarthritis (KOA). METHODS: A cross-sectional study of 39 patients (women 71.8%, men 28.2%; mean age of 72.03 years (SD 1.15) with advanced KOA (...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Editorial Society of Bone & Joint Surgery
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672324/ https://www.ncbi.nlm.nih.gov/pubmed/33174472 http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0022.R2 |
_version_ | 1783611109210587136 |
---|---|
author | Seco-Calvo, Jesús Sánchez-Herráez, Sergio Casis, Luis Valdivia, Asier Perez-Urzelai, Itxaro Gil, Javier Echevarría, Enrique |
author_facet | Seco-Calvo, Jesús Sánchez-Herráez, Sergio Casis, Luis Valdivia, Asier Perez-Urzelai, Itxaro Gil, Javier Echevarría, Enrique |
author_sort | Seco-Calvo, Jesús |
collection | PubMed |
description | AIMS: To analyze the potential role of synovial fluid peptidase activity as a measure of disease burden and predictive biomarker of progression in knee osteoarthritis (KOA). METHODS: A cross-sectional study of 39 patients (women 71.8%, men 28.2%; mean age of 72.03 years (SD 1.15) with advanced KOA (Ahlbäck grade ≥ 3 and clinical indications for arthrocentesis) recruited through the (Orthopaedic Department at the Complejo Asistencial Universitario de León, Spain (CAULE)), measuring synovial fluid levels of puromycin-sensitive aminopeptidase (PSA), neutral aminopeptidase (NAP), aminopeptidase B (APB), prolyl endopeptidase (PEP), aspartate aminopeptidase (ASP), glutamyl aminopeptidase (GLU) and pyroglutamyl aminopeptidase (PGAP). RESULTS: Synovial fluid peptidase activity varied significantly as a function of clinical signs, with differences in levels of PEP (p = 0.020), ASP (p < 0.001), and PGAP (p = 0. 003) associated with knee locking, PEP (p = 0.006), ASP (p = 0.001), GLU (p = 0.037), and PGAP (p = 0.000) with knee failure, and PEP (p = 0.006), ASP (p = 0.001), GLU (p = 0.037), and PGAP (p < 0.001) with knee effusion. Further, patients with the greatest functional impairment had significantly higher levels of APB (p = 0.005), PEP (p = 0.005), ASP (p = 0.006), GLU (p = 0.020), and PGAP (p < 0.001) activity, though not of NAP or PSA, indicating local alterations in the renin-angiotensin system. A binary logistic regression model showed that PSA was protective (p = 0.005; Exp (B) 0.949), whereas PEP (p = 0.005) and GLU were risk factors (p = 0.012). CONCLUSION: These results suggest synovial fluid peptidase activity could play a role as a measure of disease burden and predictive biomarker of progression in KOA. Cite this article: Bone Joint Res 2020;9(11):789–797. |
format | Online Article Text |
id | pubmed-7672324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The British Editorial Society of Bone & Joint Surgery |
record_format | MEDLINE/PubMed |
spelling | pubmed-76723242020-11-19 Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study Seco-Calvo, Jesús Sánchez-Herráez, Sergio Casis, Luis Valdivia, Asier Perez-Urzelai, Itxaro Gil, Javier Echevarría, Enrique Bone Joint Res Arthritis AIMS: To analyze the potential role of synovial fluid peptidase activity as a measure of disease burden and predictive biomarker of progression in knee osteoarthritis (KOA). METHODS: A cross-sectional study of 39 patients (women 71.8%, men 28.2%; mean age of 72.03 years (SD 1.15) with advanced KOA (Ahlbäck grade ≥ 3 and clinical indications for arthrocentesis) recruited through the (Orthopaedic Department at the Complejo Asistencial Universitario de León, Spain (CAULE)), measuring synovial fluid levels of puromycin-sensitive aminopeptidase (PSA), neutral aminopeptidase (NAP), aminopeptidase B (APB), prolyl endopeptidase (PEP), aspartate aminopeptidase (ASP), glutamyl aminopeptidase (GLU) and pyroglutamyl aminopeptidase (PGAP). RESULTS: Synovial fluid peptidase activity varied significantly as a function of clinical signs, with differences in levels of PEP (p = 0.020), ASP (p < 0.001), and PGAP (p = 0. 003) associated with knee locking, PEP (p = 0.006), ASP (p = 0.001), GLU (p = 0.037), and PGAP (p = 0.000) with knee failure, and PEP (p = 0.006), ASP (p = 0.001), GLU (p = 0.037), and PGAP (p < 0.001) with knee effusion. Further, patients with the greatest functional impairment had significantly higher levels of APB (p = 0.005), PEP (p = 0.005), ASP (p = 0.006), GLU (p = 0.020), and PGAP (p < 0.001) activity, though not of NAP or PSA, indicating local alterations in the renin-angiotensin system. A binary logistic regression model showed that PSA was protective (p = 0.005; Exp (B) 0.949), whereas PEP (p = 0.005) and GLU were risk factors (p = 0.012). CONCLUSION: These results suggest synovial fluid peptidase activity could play a role as a measure of disease burden and predictive biomarker of progression in KOA. Cite this article: Bone Joint Res 2020;9(11):789–797. The British Editorial Society of Bone & Joint Surgery 2020-11-11 /pmc/articles/PMC7672324/ /pubmed/33174472 http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0022.R2 Text en © 2020 Author(s) et al. https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND 4.0) licence, which permits the copying and redistribution of the work only, and provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Arthritis Seco-Calvo, Jesús Sánchez-Herráez, Sergio Casis, Luis Valdivia, Asier Perez-Urzelai, Itxaro Gil, Javier Echevarría, Enrique Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study |
title | Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study |
title_full | Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study |
title_fullStr | Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study |
title_full_unstemmed | Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study |
title_short | Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study |
title_sort | synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study |
topic | Arthritis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672324/ https://www.ncbi.nlm.nih.gov/pubmed/33174472 http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0022.R2 |
work_keys_str_mv | AT secocalvojesus synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy AT sanchezherraezsergio synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy AT casisluis synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy AT valdiviaasier synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy AT perezurzelaiitxaro synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy AT giljavier synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy AT echevarriaenrique synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy |